Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQD3524 in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia
NCT07512596Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of colistimethate sodium in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2026; status: recruiting.
02
Drugs
colistimethate sodium
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07512596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512596.